Estradiol transdermal - Merck KGaA

Drug Profile

Estradiol transdermal - Merck KGaA

Alternative Names: Fem7; Feminova; Femsept; FemSeven; Femseven

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck KGaA
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 20 Aug 2013 Biomarkers information updated
  • 31 Dec 2002 Fem7® has been licensed to Gedeon Richter in many Central European, Eastern European and Commonwealth of Independent States countries
  • 31 Dec 1998 Launched for Menopausal syndrome in Europe (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top